Serum urate: a biomarker or treatment target in pediatric hypertension?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology
PubMed 23736817 · doi:10.1097/HCO.0b013e32836205ff
What was done
Narrative review synthesizing published literature on the relationship between serum uric acid levels and essential hypertension in children and adolescents, focusing on its utility as a diagnostic biomarker, the effects of urate-lowering agents (allopurinol and probenecid), and the role of dietary fructose.
What was found
The abstract reports no numerical data or effect sizes. It qualitatively describes a strong correlation between elevated uric acid levels and essential hypertension in pediatric populations, notes that small studies demonstrate blood pressure reduction with allopurinol and probenecid in adolescents, and mentions an unconfirmed clinical effect of fructose reduction.
Why it matters
It highlights serum uric acid as a potential diagnostic marker and modifiable target during the early, reversible phase of new-onset pediatric essential hypertension.
Limits
The abstract provides no sample sizes, effect estimates, or numerical data. As a narrative review, it lacks systematic search criteria, and existing intervention evidence is limited to small adolescent cohorts with unproven long-term safety profiles.
Cited by
- supports Approximately 90% of adolescents with newly diagnosed primary essential hypertension have elevated serum uric acid, compared to under 5% of normotensive controls.